1231 related articles for article (PubMed ID: 26202488)
21. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
22. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.
Silverman SL; Chines AA; Kendler DL; Kung AW; Teglbjærg CS; Felsenberg D; Mairon N; Constantine GD; Adachi JD;
Osteoporos Int; 2012 Jan; 23(1):351-63. PubMed ID: 21779819
[TBL] [Abstract][Full Text] [Related]
23. Denosumab in postmenopausal women with osteoporosis and diabetes: Subgroup analysis of FREEDOM and FREEDOM extension.
Ferrari S; Eastell R; Napoli N; Schwartz A; Hofbauer LC; Chines A; Wang A; Pannacciulli N; Cummings SR
Bone; 2020 May; 134():115268. PubMed ID: 32058020
[TBL] [Abstract][Full Text] [Related]
24. Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment.
Ferrari S; Butler PW; Kendler DL; Miller PD; Roux C; Wang AT; Huang S; Wagman RB; Lewiecki EM
J Clin Endocrinol Metab; 2019 Aug; 104(8):3450-3461. PubMed ID: 31125092
[TBL] [Abstract][Full Text] [Related]
25. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
[TBL] [Abstract][Full Text] [Related]
26. One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study.
Lewiecki EM; Dinavahi RV; Lazaretti-Castro M; Ebeling PR; Adachi JD; Miyauchi A; Gielen E; Milmont CE; Libanati C; Grauer A
J Bone Miner Res; 2019 Mar; 34(3):419-428. PubMed ID: 30508316
[TBL] [Abstract][Full Text] [Related]
27. A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture.
Palacios S; Silverman SL; de Villiers TJ; Levine AB; Goemaere S; Brown JP; De Cicco Nardone F; Williams R; Hines TL; Mirkin S; Chines AA;
Menopause; 2015 Aug; 22(8):806-13. PubMed ID: 25668306
[TBL] [Abstract][Full Text] [Related]
28. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Wang H; Liu Y; San Martin J
J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
[TBL] [Abstract][Full Text] [Related]
29. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial.
Langdahl BL; Teglbjærg CS; Ho PR; Chapurlat R; Czerwinski E; Kendler DL; Reginster JY; Kivitz A; Lewiecki EM; Miller PD; Bolognese MA; McClung MR; Bone HG; Ljunggren Ö; Abrahamsen B; Gruntmanis U; Yang YC; Wagman RB; Mirza F; Siddhanti S; Orwoll E
J Clin Endocrinol Metab; 2015 Apr; 100(4):1335-42. PubMed ID: 25607608
[TBL] [Abstract][Full Text] [Related]
30. Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease.
Broadwell A; Chines A; Ebeling PR; Franek E; Huang S; Smith S; Kendler D; Messina O; Miller PD
J Clin Endocrinol Metab; 2021 Jan; 106(2):397-409. PubMed ID: 33211870
[TBL] [Abstract][Full Text] [Related]
31. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis.
Reginster JY; Kaufman JM; Goemaere S; Devogelaer JP; Benhamou CL; Felsenberg D; Diaz-Curiel M; Brandi ML; Badurski J; Wark J; Balogh A; Bruyère O; Roux C
Osteoporos Int; 2012 Mar; 23(3):1115-22. PubMed ID: 22124575
[TBL] [Abstract][Full Text] [Related]
32. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
[TBL] [Abstract][Full Text] [Related]
33. Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM study extension.
Brown JP; Reid IR; Wagman RB; Kendler D; Miller PD; Jensen JE; Bolognese MA; Daizadeh N; Valter I; Zerbini CA; Dempster DW
J Bone Miner Res; 2014 Sep; 29(9):2051-6. PubMed ID: 24692050
[TBL] [Abstract][Full Text] [Related]
34. Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients.
Kamimura M; Nakamura Y; Ikegami S; Uchiyama S; Kato H; Taguchi A
Osteoporos Int; 2017 Feb; 28(2):559-566. PubMed ID: 27650642
[TBL] [Abstract][Full Text] [Related]
35. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension.
Cummings SR; Ferrari S; Eastell R; Gilchrist N; Jensen JB; McClung M; Roux C; Törring O; Valter I; Wang AT; Brown JP
J Bone Miner Res; 2018 Feb; 33(2):190-198. PubMed ID: 29105841
[TBL] [Abstract][Full Text] [Related]
36. Long-term effect of denosumab on bone microarchitecture as assessed by tissue thickness-adjusted trabecular bone score in postmenopausal women with osteoporosis: results from FREEDOM and its open-label extension.
Hans D; McDermott M; Huang S; Kim M; Shevroja E; McClung M
Osteoporos Int; 2023 Jun; 34(6):1075-1084. PubMed ID: 36862192
[TBL] [Abstract][Full Text] [Related]
37. Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis.
Dempster DW; Brown JP; Fahrleitner-Pammer A; Kendler D; Rizzo S; Valter I; Wagman RB; Yin X; Yue SV; Boivin G
J Clin Endocrinol Metab; 2018 Jul; 103(7):2498-2509. PubMed ID: 29672714
[TBL] [Abstract][Full Text] [Related]
38. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
Black DM; Schwartz AV; Ensrud KE; Cauley JA; Levis S; Quandt SA; Satterfield S; Wallace RB; Bauer DC; Palermo L; Wehren LE; Lombardi A; Santora AC; Cummings SR;
JAMA; 2006 Dec; 296(24):2927-38. PubMed ID: 17190893
[TBL] [Abstract][Full Text] [Related]
39. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
[TBL] [Abstract][Full Text] [Related]
40. Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis.
Abdelazim IA; Abdelrazak KM; Al-Kadi M; Yehia AH; Nusair BM; Faza MA
Arch Osteoporos; 2014; 9():189. PubMed ID: 25037077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
